The AlphaLISA® immunoassay kit for human LAG-3 enables the quantitative determination of human lymphocyte-activation gene 3 (LAG-3) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
Item(s) added to cart.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Lymphocyte-activation gene 3 (LAG-3), also known as CD223, is a cell surface protein that affects T-cell function in many ways. LAG-3 is expressed on natural killer cells, plasmacytoid dendritic cells, B-cells, and activated T-cells. LAG-3 works in similar fashion to CTLA-4 and PD-1 in that it negatively regulates cellular proliferation and Treg suppression. Maturation and activation of dendritic cells is also known to be affected by LAG-3 expression. Soluble forms are in clinical development to activate dendritic cells. Anti-LAG-3 antibodies are undergoing studies for anti-cancer and autoimmune response.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|
This manual describes how to run an AlphaLISA human LAG-3 detection assay.